Biomarker Services

Customised biomarker panels to enhance all stages of therapeutic development

Innovative Biomarker Analysis Solutions

Synexa Life Sciences has over two decades experience designing biomarker strategies to support customers’ broader clinical development objectives. Our team of scientists are experts in developing optimum biomarker strategies for biomarker discovery, selection and analysis in order to meet your clinical development goals.

Synexa’s global setup aims to support research programs from translational research through to late-stage clinical trials and post-marketing surveillance. Working collaboratively, we focus on careful selection of markers to ensure results that support decision-making and progression through the therapeutic pipeline with confidence.

Specialised Biomarker Services

High Sensitivity

Biomarker Consultation

Advice on the optimal selection of biomarkers in the context of the drug, disease and budget.

Biomarker Assay Development & Validation

Development, optimisation and validation of biomarker assays across a wide range of matrices and technology platforms.

Biomarker Analysis

Biomarker analysis of clinical samples for exploratory or clinical trial settings.

Biomarker Solutions

Comprehensive biomarker solutions, from biomarker discovery through to selection and biomarker assay development

Biomarker Platforms

Our technology platforms are robust, reliable and reputable in the clinical field and provide comprehensive and detailed data readouts for your application.

FAQ

What guidelines does Synexa use to validate biomarker assays?

None; Synexa’s biomarker assays are validated as fit for purpose based on their context of use.

Whilst Synexa specialises in the development of complex and custom-designed assays, Synexa does offer pre-validated biomarker assays – depending on the context of use, sample type and duration of the study.

BM analysis often requires flexible thinking and delivery to allow for pre-analyical stability considerations, complex data interpretations and outputs and fit for purpose validations. Our experince allows for this and more, providing quality data without the rigidity of PK workflows.

Yes, we recommend using MSD’s S-PLEX ultrasensitive assay platform for the measurement of analytes at extremely low concentrations or to reduce required sample volume / critical reagent usage.

Improving the quality of human health

Contact us

Discuss biomarker and bioanalytical solutions to accelerate your therapeutic pipeline